RxDoctor Payments Data

Rupal Shah, MD

Family Medicine · Corona, CANPI 1396730560

Payments from drug & device makers

$5,969in general payments, 2019–2025

Across 189 payments — averaging $31.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AstraZeneca$2K
  • Amgen$1K
  • Boehringer Ingelheim$214
  • AbbVie$154
  • Gilead$120
  • plus $672 from 18 others

What the payments were for

  • Consulting fees$1,20020%
  • Travel & lodging$2935%
  • Food & beverage$4,47675%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,969 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$103,489
Medicare patients
96
Services billed
996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol31$44,599
Repatha SureclickEvolocumab51$38,777
EliquisApixaban40$32,049
XareltoRivaroxaban28$30,446
JardianceEmpagliflozin21$20,097
OzempicSemaglutide18$16,577
TrulicityDulaglutide13$12,499
MounjaroTirzepatide12$12,217
InvokanaCanagliflozin14$10,339
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,927
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,044
Atorvastatin Calcium491$4,293
Divalproex Sodium ErDivalproex Sodium11$4,225
Losartan Potassium299$2,576
Albuterol Sulfate HfaAlbuterol Sulfate96$2,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,514$44,59931 claims
Johnson & JohnsonXarelto, Invokana$38$40,78542 claims
PfizerEliquis$35$32,04940 claims
Lilly USA, LLCTrulicity, Mounjaro$45$24,71625 claims
Boehringer IngelheimJardiance$214$20,09721 claims
Novo NordiskOzempic$29$16,57718 claims
GSKTrelegy Ellipta$68$6,92711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →